Huang Yifan, Lyu Xiaohang, Kam Yiu-Wing
Division of Natural and Applied Science, Duke Kunshan University, No. 8 Duke Avenue, Kunshan 215316, China.
Vaccines (Basel). 2025 Aug 20;13(8):881. doi: 10.3390/vaccines13080881.
Non-communicable diseases (NCDs) have become a major threat to global public health, with the disease burden particularly severe in developing countries, China being one of them. The preventive and control effects of traditional treatment methods on NCDs are limited, and innovative strategies are urgently needed. In recent years, vaccine technology has expanded from the field of infectious diseases to non-communicable diseases (NCDs). Therapeutic vaccines have shown the potential to intervene in chronic diseases through immunomodulation, but their research and development (R & D), as well as promotion, still face multiple challenges.
This article systematically reviews the current development status of NCD vaccines worldwide and points out the imbalance in their matching with disease burden: current research focuses on the field of cancer, while there is a lack of targeted vaccines for high-burden diseases such as hypertension and chronic kidney disease; the progress of independent R & D in China lags behind, and there are implementation obstacles such as uneven distribution of medical resources between urban and rural areas and low public willingness to be vaccinated.
By analyzing the biological mechanisms of NCD vaccines and non-biological challenges, phased solutions are proposed: In the short term, focus on target discovery and improvement of vaccine accessibility. In the medium term, strengthen multi-center clinical trials and international technology sharing. In the long term, build a digital health monitoring system and a public-private partnership financing model.
The breakthrough of NCD vaccines requires interdisciplinary collaboration and systematic policy support. Their successful application will reshape the paradigm of chronic disease prevention and control, providing a new path for global health equity.
非传染性疾病已成为全球公共卫生的重大威胁,疾病负担在发展中国家尤为严重,中国是其中之一。传统治疗方法对非传染性疾病的预防和控制效果有限,迫切需要创新策略。近年来,疫苗技术已从传染病领域扩展到非传染性疾病。治疗性疫苗已显示出通过免疫调节干预慢性病的潜力,但其研发以及推广仍面临多重挑战。
本文系统综述了全球非传染性疾病疫苗的当前发展状况,并指出其与疾病负担匹配方面的不平衡:当前研究集中在癌症领域,而对于高血压和慢性肾病等高负担疾病缺乏针对性疫苗;中国自主研发进展滞后,存在城乡医疗资源分布不均、公众接种意愿低等实施障碍。
通过分析非传染性疾病疫苗的生物学机制和非生物学挑战,提出分阶段解决方案:短期内,专注于靶点发现和提高疫苗可及性。中期,加强多中心临床试验和国际技术共享。长期,建立数字健康监测系统和公私合作伙伴关系融资模式。
非传染性疾病疫苗的突破需要跨学科合作和系统性政策支持。它们的成功应用将重塑慢性病防控范式,为全球健康公平提供新路径。